AGF Investments Inc. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 87.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,862 shares of the biopharmaceutical company’s stock after acquiring an additional 2,262 shares during the period. AGF Investments […]
Kavar Capital Partners Group LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 86.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,930 shares of the biopharmaceutical company’s stock after selling 17,995 shares during the quarter. Kavar Capital Partners Group […]
TCW Group Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 3.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 699,145 shares of the biopharmaceutical company’s stock after purchasing an additional 25,768 shares during the quarter. TCW Group […]
Tokio Marine Asset Management Co. Ltd. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 1.4% during the 4th quarter, HoldingsChannel reports. The fund owned 18,959 shares of the biopharmaceutical company’s stock after buying an additional 255 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Gilead Sciences were […]
National Bank of Canada FI purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) in the 4th quarter, HoldingsChannel reports. The fund purchased 511,238 shares of the biopharmaceutical company’s stock, valued at approximately $37,114,000. Several other hedge funds also recently modified their holdings of the company. Morgan Stanley boosted its position in […]